Literature DB >> 35618424

Application of 7T MRS to High-Grade Gliomas.

L McCarthy1, G Verma2, G Hangel3,4, A Neal5,6, B A Moffat7, J P Stockmann8,9, O C Andronesi8,9, P Balchandani2, C G Hadjipanayis10.   

Abstract

MRS, including single-voxel spectroscopy and MR spectroscopic imaging, captures metabolites in high-grade gliomas. Emerging evidence indicates that 7T MRS may be more sensitive to aberrant metabolic activity than lower-field strength MRS. However, the literature on the use of 7T MRS to visualize high-grade gliomas has not been summarized. We aimed to identify metabolic information provided by 7T MRS, optimal spectroscopic sequences, and areas for improvement in and new applications for 7T MRS. Literature was found on PubMed using "high-grade glioma," "malignant glioma," "glioblastoma," "anaplastic astrocytoma," "7T," "MR spectroscopy," and "MR spectroscopic imaging." 7T MRS offers higher SNR, modestly improved spatial resolution, and better resolution of overlapping resonances. 7T MRS also yields reduced Cramér-Rao lower bound values. These features help to quantify D-2-hydroxyglutarate in isocitrate dehydrogenase 1 and 2 gliomas and to isolate variable glutamate, increased glutamine, and increased glycine with higher sensitivity and specificity. 7T MRS may better characterize tumor infiltration and treatment effect in high-grade gliomas, though further study is necessary. 7T MRS will benefit from increased sample size; reductions in field inhomogeneity, specific absorption rate, and acquisition time; and advanced editing techniques. These findings suggest that 7T MRS may advance understanding of high-grade glioma metabolism, with reduced Cramér-Rao lower bound values and better measurement of smaller metabolite signals. Nevertheless, 7T is not widely used clinically, and technical improvements are necessary. 7T MRS isolates metabolites that may be valuable therapeutic targets in high-grade gliomas, potentially resulting in wider ranging neuro-oncologic applications. © by American Journal of Neuroradiology.

Entities:  

Year:  2022        PMID: 35618424      PMCID: PMC9575545          DOI: 10.3174/ajnr.A7502

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  179 in total

1.  In vivo 1H NMR spectroscopy of the human brain at 7 T.

Authors:  I Tkác; P Andersen; G Adriany; H Merkle; K Ugurbil; R Gruetter
Journal:  Magn Reson Med       Date:  2001-09       Impact factor: 4.668

2.  Fast high-resolution brain metabolite mapping on a clinical 3T MRI by accelerated 1 H-FID-MRSI and low-rank constrained reconstruction.

Authors:  Antoine Klauser; Sebastien Courvoisier; Jeffrey Kasten; Michel Kocher; Matthieu Guerquin-Kern; Dimitri Van De Ville; Francois Lazeyras
Journal:  Magn Reson Med       Date:  2018-12-18       Impact factor: 4.668

3.  Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.

Authors:  J Cha; S T Kim; H-J Kim; B-J Kim; Y K Kim; J Y Lee; P Jeon; K H Kim; D-S Kong; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

4.  Serum lactate levels are associated with glioma malignancy grade.

Authors:  Mariana Branco; Paulo Linhares; Bruno Carvalho; Patrícia Santos; Bruno M Costa; Rui Vaz
Journal:  Clin Neurol Neurosurg       Date:  2019-10-01       Impact factor: 1.876

5.  Safety Considerations of 7-T MRI in Clinical Practice.

Authors:  Michael N Hoff; Alexander McKinney; Frank G Shellock; Ulrich Rassner; Tobias Gilk; Robert E Watson; Todd D Greenberg; Jerry Froelich; Emanuel Kanal
Journal:  Radiology       Date:  2019-07-16       Impact factor: 11.105

Review 6.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Authors:  Dieta Brandsma; Lukas Stalpers; Walter Taal; Peter Sminia; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2008-05       Impact factor: 41.316

7.  Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

Authors:  Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt
Journal:  Radiology       Date:  2012-11-30       Impact factor: 11.105

8.  Reproducibility of 2D GluCEST in healthy human volunteers at 7 T.

Authors:  Ravi Prakash Reddy Nanga; Catherine DeBrosse; Dushyant Kumar; David Roalf; Brendan McGeehan; Kevin D'Aquilla; Arijitt Borthakur; Hari Hariharan; Damodara Reddy; Mark Elliott; John A Detre; Cynthia Neill Epperson; Ravinder Reddy
Journal:  Magn Reson Med       Date:  2018-05-25       Impact factor: 4.668

Review 9.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Authors:  Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

10.  Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death.

Authors:  Simona Daniele; Chiara Giacomelli; Elisa Zappelli; Carlotta Granchi; Maria Letizia Trincavelli; Filippo Minutolo; Claudia Martini
Journal:  Sci Rep       Date:  2015-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.